Monopar Therapeutics Inc (MNPR) AI Stock Analysis

• Market Cap: $214.55M
• Dividend Yield: N/A
• Average Volume (3M): 21.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.36
• Revenue Growth: N/A
• EPS Growth: -35.23%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -1.22
• Shares Outstanding: 6,112,593
• 10 Day Avg. Volume: 18,807
• 30 Day Avg. Volume: 21,896
• PEG Ratio: <0.01
• Price to Book (P/B): 2.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -37.63
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: $52.00
• Price Target Upside: 48.15% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Monopar’s overall stock score is primarily affected by its financial performance challenges, such as negative cash flows and lack of revenue. However, the strong cash position and debt-free status provide some stability. The technical indicators show neutral market sentiment, while the new CFO appointment brings a positive strategic outlook. The valuation reflects typical biotech hurdles with a negative P/E ratio.

Positive Factors

Drug Development

ALXN-1840 is considered a derisked drug for the treatment of Wilson's disease and a commercial launch would provide revenue to fund the development of their radiopharmaceutical.

Market Potential

The total addressable market for ALXN1840 could reach $420M in the U.S. alone, based on an estimate of 10,000-12,000 WD patients in the U.S.

Strategic Partnerships

Monopar Therapeutics announced a strategic agreement with Alexion, AstraZeneca Rare Disease, for the exclusive worldwide in-licensing of ALXN-1840 for the treatment of Wilson's disease.

Negative Factors

Financial Performance

The company reported no revenues, in line with consensus estimates, and a net loss of $4.11 per share, compared to consensus estimated net loss of $1.29 per share.

Investor Focus

Investors are expected to be more focused on later-stage ALXN-1840 and anticipate incremental updates from MNPR-101-Lu to have a muted impact on share price in the near term.

Regulatory Challenges

Providing proof of fecal excretion of copper might require an additional study, posing a potential regulatory hurdle for ALXN1840's approval.

Monopar Therapeutics Inc Business Overview & Revenue Model

Company Description

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

How the Company Makes Money

Monopar Therapeutics Inc. primarily makes money through the development and potential commercialization of its drug candidates. The company is in a clinical-stage, meaning its revenue model is largely oriented towards the successful advancement of its drug pipeline through clinical trials. Revenue streams may include potential milestone payments and royalties from partnerships or licensing agreements with larger pharmaceutical companies. Additionally, Monopar may receive government grants or funding from non-profit organizations to support its research and development efforts. The company's financial success is heavily reliant on the clinical and regulatory success of its product candidates, as well as its ability to establish strategic collaborations.

Monopar Therapeutics Inc Financial Statement Overview

Summary

Monopar Therapeutics faces typical early-stage biotech challenges with no revenue and ongoing losses. Despite a strong cash position and no debt, the reliance on external financing and negative cash flows pose risks. The focus on transitioning from R&D to commercialization is crucial for long-term financial sustainability.

Income Statement

Monopar Therapeutics Inc has shown consistent negative EBIT and net income figures over the years, reflecting ongoing operational challenges. The company has not generated any revenue, which is expected in early-stage biotech firms but poses significant risks for sustainability without revenue growth. The lack of gross profit margin and net profit margin metrics further underscores the absence of sales revenue. The substantial increase in net loss in 2024 signals heightened financial strain.

Balance Sheet

The balance sheet reveals a strong cash position with no debt, which is a positive indicator of financial flexibility. The equity ratio remains healthy, suggesting that the company is well-capitalized. However, the company's assets and equity have become more volatile, as evidenced by the large equity increase in 2024, potentially from financing activities. The absence of revenue generation remains a challenge for long-term viability.

Cash Flow

Operating cash flows have been negative consistently, indicating cash outflows from core operations. The significant increase in financing cash flows in 2024 suggests reliance on external funding for cash needs. Free cash flow remains negative, which is typical for biotech firms in development stages but highlights the need for successful product development and commercialization to improve cash flow health.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00
	EBIT
-16.16B	-8.83M	-10.54M	-9.13M	-6.51M
	EBITDA
-15.59M	429.04K	0.00	0.00	0.00
	Net Income Common Stockholders
-15.59B	-8.40M	-10.49M	-9.08M	-6.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
60.21M	7.27M	13.12M	20.30M	16.74M
	Total Assets
60.29M	7.35M	13.23M	20.52M	16.87M
	Total Debt
0.00	0.00	8.41K	0.00	0.00
	Net Debt
-45.82M	-7.27M	-8.18M	-20.30M	-16.74M
	Total Liabilities
5.25M	1.76M	3.14M	1.58M	1.18M
	Stockholders Equity
55.04B	5.59M	10.09M	18.94M	15.69M
Cash Flow		Free Cash Flow
-6.40M	-7.86M	-7.23M	-7.32M	-4.66M
	Operating Cash Flow
-6.40M	-7.86M	-7.23M	-7.32M	-4.66M
	Investing Cash Flow
-14.34M	4.93M	-4.92M	0.00	0.00
	Financing Cash Flow
59.29M	2.03M	32.87K	10.88M	8.18M

Monopar Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 35.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Negative. The current price of 35.1 is below the 20-day moving average (MA) of 40.94, below the 50-day MA of 36.73, and above the 200-day MA of 22.51, indicating a neutral trend. The MACD of 0.61 indicates Positive momentum. The RSI at 42.63 is Neutral, neither overbought nor oversold. The STOCH value of 25.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MNPR.

Monopar Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$251.67M	―	-41.31%	―	―	-7.93%
Sector *	52 Neutral	$5.21B	3.49	-43.30%	2.83%	14.70%	-0.24%
MNPR	48 Neutral	$214.55M	―	-51.42%	―	―	-35.23%
ITOS	44 Neutral	$264.85M	―	-23.68%	―	―	14.60%
XOMA	43 Neutral	$289.14M	―	-16.20%	―	498.72%	49.92%
CDTX	42 Neutral	$252.00M	―	-299.58%	―	-99.35%	-260.33%
ANNX	38 Underperform	$175.54M	―	-66.13%	―	―	43.21%

Monopar Therapeutics Inc Corporate Events

Monopar Therapeutics Appoints Quan Vu as New CFO

Monopar Therapeutics Inc. announced the termination of Karthik Radhakrishnan’s employment as Chief Financial Officer, principal financial officer, and principal accounting officer on February 28, 2025. The company’s Board of Directors appointed Quan Vu as the new CFO, effective March 3, 2025. Vu brings extensive experience in corporate and financial strategy, having previously served in various leadership roles in the biopharmaceutical and investment banking sectors. This leadership change is expected to impact Monopar’s financial strategy and operations positively.

Monopar Therapeutics Appoints Lavina Talukdar to Board

Monopar Therapeutics Inc. announced the resignation of Michael J. Brown from its Board of Directors effective February 19, 2025, and the appointment of Lavina Talukdar to the Board on February 21, 2025. Talukdar, who is currently the Senior Vice President, Head of Investor Relations at Moderna Inc., brings over 20 years of experience in investor relations and healthcare investments. Her appointment is expected to enhance Monopar’s strategic direction and governance, as she will also serve on several key committees within the company.